Denosumab和泼尼松治疗的不典型股骨骨折伴多发性椎体压缩性骨折、虚弱和生活质量下降

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Gayle Frazzetta MD, FAAFP
{"title":"Denosumab和泼尼松治疗的不典型股骨骨折伴多发性椎体压缩性骨折、虚弱和生活质量下降","authors":"Gayle Frazzetta MD, FAAFP","doi":"10.1016/j.jocd.2023.101390","DOIUrl":null,"url":null,"abstract":"<div><h3>Case Description</h3><p>Atypical Femur Fracture<span><span><span> on Denosumab and </span>Prednisone<span><span><span> with Multiple Vertebral Compression Fractures, </span>Frailty, and Diminishing </span>Quality of Life CO is a 70yo female with end-stage O2 and steroid dependent COPD/asthma with multiple thoracic and lumbar compression fractures contributing/causing non-ambulatory status and impairment of ADL's. She was treated with denosumab(Prolia) 2011-2015 until atypical femur fracture (figure 1) and </span></span>metatarsal fracture occurred. She was on risedronate(Actonel) prior to this, 2004-2007, until side effects of esophageal spasm/GI irritation occurred and therapy was discontinued. Teriparatide(Forteo) was offered after discontinuing denosumab however patient noted possibility of bone cancer and declined it.</span></p><p><span><span>Compression fracture bracing and walker to wheelchair transition occurred about 2 months prior to referral for treatment<span><span> recommendations. PMH: osteoporosis, COPD, asthma, </span>osteoarthritis<span><span>, low back pain with scoliosis and </span>kyphosis, hypertension, previous smoker-quit 2010 (+/-25 pack year hx), </span></span></span>hypokalemia<span><span><span>, ocular migraines PSH: femur repair, cataracts, </span>tubal ligation Meds: </span>lisinopril<span><span> 40mg, prednisone 10mg alternating with 5mg qd, tiotropium inhaled, montelukast 10mg, </span>symbicort<span><span><span> 160/4.5 2 puffs bid, albuterol </span>prn (uses daily), ipratropium/alb </span>nebs<span> bid prn, potassium chloride 20meq qd, </span></span></span></span></span>fluticasone<span><span><span> NS qHS, cetirizine<span> 10mg bid, cyclobenzaprine 5mg prn, acetaminophen prn Supplements: </span></span>multivitamin, glucosamine/chondroitin qd, Vit D 2000IU qd, Ca citrate/D 315-200 qd FamHX: mother: breast cancer &amp; OP Social Hx: married, retired piano instructor, rare alcohol, attends pulmonary rehab 2x/week until recent compression fracture, now unable due to pain </span>ROS<span><span>: unintended weight loss, prednisone dependent x 10 years; unable to tolerate multiple attempts at prednisone taper, significant pain reported from new compression fracture with mobility impairment Imaging Studies XRays: Thoracic spine (2 months prior to eval)1. Scoliosis 2. Multilevel age- indeterminate compression fractures, T10-12. Estimated 50% </span>vertebral body height loss, no change. Mild, anterior compression deformity L1, stable compared to 2018. 2 week follow-up X-ray to above:</span></span></p><p><span><span>1. New mild anterior compression deformity of L2 with approximately 15% vertebral height loss. 2. Unchanged T10-L1 compression fractures. 4mm anterolisthesis of L4 on L5 without change. DXA: recent; Hip T score, total -3.5, </span>femoral neck -4.1, Spine (L1-4) T score -3.0 Comparison to study done 5 years prior: Hip: loss of 16.3%, spine: stable Labs: (Pertinent) </span>Vitamin D<span><span> 35, CBC: WBC 11.7, Hgb 14.2, platelets 324, CMP: n'l, Alk phos: n'l, Ca 9.9, TSH n'l PE: Height; original 4’ 8.5” current 4’ 5.5”, weight 88#, BMI 21, 02: 90% on 3 liters Alert, spry, cognition intact, in wheelchair, labored breathing, prominent thoracic kyphosis, back brace in place. Patient request to “heal </span>vertebrae and have ability to walk without a walker and back brace.” A treatment dilemma given history of atypical femur fracture while on denosumab and prednisone and continued progression/worsening of compression fractures, frailty and diminishing quality of life.</span></p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Atypical Femur Fracture on Denosumab and Prednisone with Multiple Vertebral Compression Fractures, Frailty and Diminishing Quality of Life\",\"authors\":\"Gayle Frazzetta MD, FAAFP\",\"doi\":\"10.1016/j.jocd.2023.101390\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Case Description</h3><p>Atypical Femur Fracture<span><span><span> on Denosumab and </span>Prednisone<span><span><span> with Multiple Vertebral Compression Fractures, </span>Frailty, and Diminishing </span>Quality of Life CO is a 70yo female with end-stage O2 and steroid dependent COPD/asthma with multiple thoracic and lumbar compression fractures contributing/causing non-ambulatory status and impairment of ADL's. She was treated with denosumab(Prolia) 2011-2015 until atypical femur fracture (figure 1) and </span></span>metatarsal fracture occurred. She was on risedronate(Actonel) prior to this, 2004-2007, until side effects of esophageal spasm/GI irritation occurred and therapy was discontinued. Teriparatide(Forteo) was offered after discontinuing denosumab however patient noted possibility of bone cancer and declined it.</span></p><p><span><span>Compression fracture bracing and walker to wheelchair transition occurred about 2 months prior to referral for treatment<span><span> recommendations. PMH: osteoporosis, COPD, asthma, </span>osteoarthritis<span><span>, low back pain with scoliosis and </span>kyphosis, hypertension, previous smoker-quit 2010 (+/-25 pack year hx), </span></span></span>hypokalemia<span><span><span>, ocular migraines PSH: femur repair, cataracts, </span>tubal ligation Meds: </span>lisinopril<span><span> 40mg, prednisone 10mg alternating with 5mg qd, tiotropium inhaled, montelukast 10mg, </span>symbicort<span><span><span> 160/4.5 2 puffs bid, albuterol </span>prn (uses daily), ipratropium/alb </span>nebs<span> bid prn, potassium chloride 20meq qd, </span></span></span></span></span>fluticasone<span><span><span> NS qHS, cetirizine<span> 10mg bid, cyclobenzaprine 5mg prn, acetaminophen prn Supplements: </span></span>multivitamin, glucosamine/chondroitin qd, Vit D 2000IU qd, Ca citrate/D 315-200 qd FamHX: mother: breast cancer &amp; OP Social Hx: married, retired piano instructor, rare alcohol, attends pulmonary rehab 2x/week until recent compression fracture, now unable due to pain </span>ROS<span><span>: unintended weight loss, prednisone dependent x 10 years; unable to tolerate multiple attempts at prednisone taper, significant pain reported from new compression fracture with mobility impairment Imaging Studies XRays: Thoracic spine (2 months prior to eval)1. Scoliosis 2. Multilevel age- indeterminate compression fractures, T10-12. Estimated 50% </span>vertebral body height loss, no change. Mild, anterior compression deformity L1, stable compared to 2018. 2 week follow-up X-ray to above:</span></span></p><p><span><span>1. New mild anterior compression deformity of L2 with approximately 15% vertebral height loss. 2. Unchanged T10-L1 compression fractures. 4mm anterolisthesis of L4 on L5 without change. DXA: recent; Hip T score, total -3.5, </span>femoral neck -4.1, Spine (L1-4) T score -3.0 Comparison to study done 5 years prior: Hip: loss of 16.3%, spine: stable Labs: (Pertinent) </span>Vitamin D<span><span> 35, CBC: WBC 11.7, Hgb 14.2, platelets 324, CMP: n'l, Alk phos: n'l, Ca 9.9, TSH n'l PE: Height; original 4’ 8.5” current 4’ 5.5”, weight 88#, BMI 21, 02: 90% on 3 liters Alert, spry, cognition intact, in wheelchair, labored breathing, prominent thoracic kyphosis, back brace in place. Patient request to “heal </span>vertebrae and have ability to walk without a walker and back brace.” A treatment dilemma given history of atypical femur fracture while on denosumab and prednisone and continued progression/worsening of compression fractures, frailty and diminishing quality of life.</span></p></div>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094695023000409\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094695023000409","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

摘要

病例描述:使用Denosumab和强的松治疗的非典型股骨骨折伴多处椎体压缩性骨折、虚弱和生活质量下降。CO是一名70岁的女性,终末期O2和类固醇依赖性COPD/哮喘伴多处胸椎和腰椎压缩性骨折,导致非活动状态和ADL受损。2011-2015年,患者接受denosumab(Prolia)治疗,直至发生非典型股骨骨折(图1)和跖骨骨折。在此之前,2004-2007年,她一直在服用利塞膦酸钠(Actonel),直到出现食管痉挛/胃肠道刺激的副作用并停止治疗。停用denosumab后给予Teriparatide(Forteo),但患者注意到骨癌的可能性并拒绝使用。压缩性骨折支架和助行器到轮椅的过渡发生在转诊治疗建议的2个月前。PMH:骨质疏松症,慢性阻塞性肺病,哮喘,骨关节炎,腰痛伴脊柱侧凸和脊柱后凸,高血压,2010年戒烟史(+/-25包),低钾血症,眼部偏头痛PSH:股骨修复,白内障,输卵管结扎赖诺普利40mg,强的松10mg交替5mg qd,噻托溴铵吸入,孟鲁司特10mg, symbicort 160/4.5 2次bid,沙丁胺醇prn(每日使用),异丙托普/白藜芦醇prn,氯化钾20meq qd,氟替卡松nsqhs,西替利嗪10mg bid,环苯扎林5mg prn,对乙酰氨基酚prn补充:复合维生素,葡萄糖胺/软骨素qd,维生素D 2000IU qd,柠檬酸钙/ d315 - 200qd;OP社会Hx:已婚,退休钢琴教练,罕见的酒精,参加肺部康复2次/周,直到最近压缩性骨折,现在无法因疼痛ROS:意外体重减轻,强的松依赖x 10年;无法忍受多次强的松锥形治疗的尝试,新的压缩性骨折伴活动障碍报告了明显的疼痛。影像学研究x线:胸椎(评估前2个月)1。脊柱侧弯2。多节段年龄不确定压缩性骨折,T10-12。估计椎体高度损失50%,没有变化。轻度前路压迫畸形L1,与2018年相比稳定。2周随访x线至以上:新的L2轻度前压迫畸形伴约15%椎体高度损失。2. 未见T10-L1压缩性骨折。L4对L5抗滑脱4mm,无变化。测定仪:最近;髋关节T评分,总-3.5,股骨颈-4.1,脊柱(L1-4) T评分-3.0与5年前的研究相比:髋关节:损失16.3%,脊柱:稳定化验:(相关)维生素D 35, CBC: WBC 11.7, Hgb 14.2,血小板324,CMP: n'l, Alk phos: n'l, Ca 9.9, TSH n'l PE:身高;原来的4英尺8.5英寸,现在的4英尺5.5英寸,体重88#,BMI 21,02: 90%在3升警惕,敏捷,认知完好,坐轮椅,呼吸困难,胸部后凸突出,背部支架就位。患者要求“椎骨愈合,能够在没有助行器和背部支架的情况下行走。”在denosumab和强的松治疗期间有非典型股骨骨折的病史,压迫性骨折持续进展/恶化,虚弱和生活质量下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Atypical Femur Fracture on Denosumab and Prednisone with Multiple Vertebral Compression Fractures, Frailty and Diminishing Quality of Life

Case Description

Atypical Femur Fracture on Denosumab and Prednisone with Multiple Vertebral Compression Fractures, Frailty, and Diminishing Quality of Life CO is a 70yo female with end-stage O2 and steroid dependent COPD/asthma with multiple thoracic and lumbar compression fractures contributing/causing non-ambulatory status and impairment of ADL's. She was treated with denosumab(Prolia) 2011-2015 until atypical femur fracture (figure 1) and metatarsal fracture occurred. She was on risedronate(Actonel) prior to this, 2004-2007, until side effects of esophageal spasm/GI irritation occurred and therapy was discontinued. Teriparatide(Forteo) was offered after discontinuing denosumab however patient noted possibility of bone cancer and declined it.

Compression fracture bracing and walker to wheelchair transition occurred about 2 months prior to referral for treatment recommendations. PMH: osteoporosis, COPD, asthma, osteoarthritis, low back pain with scoliosis and kyphosis, hypertension, previous smoker-quit 2010 (+/-25 pack year hx), hypokalemia, ocular migraines PSH: femur repair, cataracts, tubal ligation Meds: lisinopril 40mg, prednisone 10mg alternating with 5mg qd, tiotropium inhaled, montelukast 10mg, symbicort 160/4.5 2 puffs bid, albuterol prn (uses daily), ipratropium/alb nebs bid prn, potassium chloride 20meq qd, fluticasone NS qHS, cetirizine 10mg bid, cyclobenzaprine 5mg prn, acetaminophen prn Supplements: multivitamin, glucosamine/chondroitin qd, Vit D 2000IU qd, Ca citrate/D 315-200 qd FamHX: mother: breast cancer & OP Social Hx: married, retired piano instructor, rare alcohol, attends pulmonary rehab 2x/week until recent compression fracture, now unable due to pain ROS: unintended weight loss, prednisone dependent x 10 years; unable to tolerate multiple attempts at prednisone taper, significant pain reported from new compression fracture with mobility impairment Imaging Studies XRays: Thoracic spine (2 months prior to eval)1. Scoliosis 2. Multilevel age- indeterminate compression fractures, T10-12. Estimated 50% vertebral body height loss, no change. Mild, anterior compression deformity L1, stable compared to 2018. 2 week follow-up X-ray to above:

1. New mild anterior compression deformity of L2 with approximately 15% vertebral height loss. 2. Unchanged T10-L1 compression fractures. 4mm anterolisthesis of L4 on L5 without change. DXA: recent; Hip T score, total -3.5, femoral neck -4.1, Spine (L1-4) T score -3.0 Comparison to study done 5 years prior: Hip: loss of 16.3%, spine: stable Labs: (Pertinent) Vitamin D 35, CBC: WBC 11.7, Hgb 14.2, platelets 324, CMP: n'l, Alk phos: n'l, Ca 9.9, TSH n'l PE: Height; original 4’ 8.5” current 4’ 5.5”, weight 88#, BMI 21, 02: 90% on 3 liters Alert, spry, cognition intact, in wheelchair, labored breathing, prominent thoracic kyphosis, back brace in place. Patient request to “heal vertebrae and have ability to walk without a walker and back brace.” A treatment dilemma given history of atypical femur fracture while on denosumab and prednisone and continued progression/worsening of compression fractures, frailty and diminishing quality of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信